TRACI FICHTER: Open Payments
NPI 1154395929 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$888 in 46 payments from 15 companies in 2025. Trend: 2023 $800 · 2024 $1,257 · 2025 $888
Food & beverage: $888
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $207 |
| Janssen Biotech, Inc. | 9 | $172 |
| Madrigal Pharmaceuticals | 8 | $154 |
| GENZYME CORPORATION | 2 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Gilead Sciences, Inc. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| Celltrion USA Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $19 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, LINZESS, CREON, RINVOQ, XIFAXAN, VEGZELMA.
Industry payments across NE — which companies pay providers there.
